RNS Number : 9370H
Uniphar PLC
08 May 2025
AGM Results
Dublin, London | 8 May 2025
Uniphar plc (the Company) is pleased to announce that at its Annual General Meeting held at 11.00 a.m. today, 8 May 2025, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie, were duly passed without amendment.
Details of votes cast are set out below:
RESOLUTION
For
For %
Against
Against %
Withheld
1
Financial Statements and Reports
153,243,069
99.17%
1,278,544
0.83%
132,837
2
Final Dividend of €3.4m
154,654,450
100.00%
0
0.00%
0
3(a)
Re-elect Ger Rabbette
153,894,576
99.51%
759,874
0.49%
0
3(b)
Re-elect Tim Dolphin
153,864,527
99.51%
761,647
0.49%
28,276
3(c)
Re-elect Paul Hogan
154,120,862
99.65%
533,588
0.35%
0
3(d)
Re-elect Sue Webb
153,923,147
99.55%
703,027
0.45%
28,276
3(e)
Re-elect Jim Gaul
146,614,423
94.80%
8,040,027
5.20%
0
3(f)
Re-elect Liz Hoctor
154,548,421
99.93%
106,029
0.07%
0
3(g)
Re-elect Maurice Pratt
151,621,344
98.04%
3,032,306
1.96%
800
3(h)
Re-elect Valerie Sick
154,335,546
99.79%
318,904
0.21%
0
4
Remuneration of Auditors
111,340,592
92.64%
8,849,615
7.36%
34,464,243
5
Authority to allot relevant securities
129,854,034
83.96%
24,800,416
16.04%
0
6
Disapplication of pre- emption rights in specified circumstances
153,651,591
99.35%
1,002,859
0.65%
0
7
Disapplication of pre- emption rights in additional circumstances
124,033,872
80.46%
30,127,960
19.54%
492,618
8
Authorise market purchases of the Company's Ordinary Shares
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Tel: +44 (0) 20 7710 7600
Matt Blawat Ben Maddison Francis North
Q4 PR
Tel: +353 (0) 1 475 1444
Iarla Mongey, Public Relations Advisor to Uniphar Group
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Medtech, Uniphar Pharma and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
Uniphar solves problems for healthcare. We sit in the middle between the manufacturers and their stakeholders, and we help them both to overcome the problems of a new, complicated healthcare environment. The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare professionals and their patients. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Medtech
Uniphar Medtech is a leading pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they cannot source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
AGMPKFBKNBKDOPK
